Esperion Therapeutics (ESPR) Equity Ratio: 2018-2025
Historic Equity Ratio for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -1.24.
- Esperion Therapeutics' Equity Ratio fell 5.21% to -1.24 in Q3 2025 from the same period last year, while for Sep 2025 it was -1.24, marking a year-over-year decrease of 5.21%. This contributed to the annual value of -1.13 for FY2024, which is 48.86% up from last year.
- Per Esperion Therapeutics' latest filing, its Equity Ratio stood at -1.24 for Q3 2025, which was up 0.73% from -1.25 recorded in Q2 2025.
- Esperion Therapeutics' 5-year Equity Ratio high stood at -0.52 for Q4 2021, and its period low was -2.21 during Q4 2023.
- Its 3-year average for Equity Ratio is -1.35, with a median of -1.25 in 2025.
- In the last 5 years, Esperion Therapeutics' Equity Ratio tumbled by 4,610.13% in 2021 and then surged by 48.86% in 2024.
- Over the past 5 years, Esperion Therapeutics' Equity Ratio (Quarterly) stood at -0.52 in 2021, then crashed by 153.02% to -1.31 in 2022, then tumbled by 69.30% to -2.21 in 2023, then spiked by 48.86% to -1.13 in 2024, then declined by 5.21% to -1.24 in 2025.
- Its Equity Ratio was -1.24 in Q3 2025, compared to -1.25 in Q2 2025 and -1.32 in Q1 2025.